CABENUVA ViiV Healthcare Pty Ltd
Product name
CABENUVA
Sponsor
Accepted date
Dec-2025
Active ingredients
cabotegravir, rilpivirine
Proposed indication
CABENUVA (cabotegravir and rilpivirine) is proposed to treat HIV 1 in adults and adolescents aged 12 years and older who weigh at least 35 kg.
It is intended for people whose HIV is already well controlled (with very low virus levels in the blood) and who do not have resistance to either of the two medicines in CABENUVA. CABENUVA is given as long acting injections.
It is intended for people whose HIV is already well controlled (with very low virus levels in the blood) and who do not have resistance to either of the two medicines in CABENUVA. CABENUVA is given as long acting injections.
Application type
C (new indication)
Publication date
Dec-2025